Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. to Present Additional Peginesatide Phase 3 Data in Dialysis Patients at the National Kidney Foundation (NKF) 2011 Spring Clinical Meeting
PALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced multiple posters on peginesatide (formerly known as Hematide™) have been accepted for presentation at the National Kidney Foundation (NKF) 2011 Spring Clinical Meeting taking place April 26-30, 2011 in Las Vegas, Nevada.